In the brains of AD patients, PP2A activity is reduced by 20% in gray matter and 40% in white matter, and PP2A inactivation involves multiple mechanisms, such as PTMs of the PP2A catalytic structure, and decreased mRNA and protein expression of the catalytic and regulatory subunits. Here, PTPA is linked to Alzheimer disease.